Il falso dilemma pubblico-privato. L’anomalia della scuola italiana nel contesto europeo

Il modello organizzativo del sistema scolastico italiano in prospettiva storica e comparata nel contesto europeo; prospettive per un adeguamento della scuola italiana al “sistema medio europeo”.- Indice #4- Introduzione, Marcello Pacini #8- Nota metodologica #14- Cap.I Il modello organizzativo del sistema scolastico italiano #18- Cap.II Il sistema medio europeo. Sistemi e problemi di un'analisi comparata #54- Cap.III Verso la deburocratizzazione. Prospettive per un adeguamento della scuola italiana al “sistema medio europeo” #114- Allegato I La struttura del sistema scolastico italiano #146- Relazioni e interventi di discussione sulla ricerca #206- Intervento On. Francesco Casati, Presidente della Commissione Istruzione e Belle Arti della Camera dei Deputati #208- Intervento Sen. Luigi Covatta, Sottosegretario di Stato alla Pubblica Istruzione #212- Intervento Sen. Salvatore Valitutti, Presidente della Commissione Istruzione Pubblica e Belle Arti del Senato della Repubblica #215- Intervento Emanuele Caruso, Dirigente Generale dell'Istruzione Tecnica, Ministero della Pubblica Istruzione #219- Intervento Mario Dupuis, Responsabile Scuola del Movimento Popolare #222- Intervento On. Laura Fincato, Vicepresidente della Commissione Istruzione e Belle Arti della Camera dei Deputati #225- Intervento Aureliana Alberici, Responsabile Scuola/Università della Direzione del P.C.I. #229- Intervento Paolo Serreri, Federazione Scuola Università C.G.I.L. #237- Intervento Daniela Silvestri, Rappresentante nazionale del Sindacato Nazionale Autonomo Lavoratori Scuola SNALS #242- Intervento Paolo Martelli, Direttore di POLITEIA - Centro per la ricerca e la formazione in politica ed etica #245- Intervento Salvatore Sechi, Professore ordinario di Storia Contemporanea, Università di Bologna #252- Intervento Piero Romei, Ricercatore dell'ISGO #257- Intervento Giovanni Bechelloni, Professore ordinario di Sociologia dei processi culturali, Università di Firenze #263- Intervento Giorgio Allulli, Censis #266- Intervento Graziella Morselli, FNISM #270- Intervento Luigi Pedrazzi, Il Mulino #274- Intervento Luciano Benadusi, Responsabile Settore Università e ricerca scientifica della Direzione Socialista #277- Intervento Mario Caronna #Coordinatore scientifico del Centro Studi di Milano #282- Intervento Adriana Rosas, Ricercatore presso il CLAS #287- Intervento Giovanni Tesoro, Ricercatore presso l’ISGO #290- Considerazioni conclusive Luisa Ribolzi, CLAS #29

Discussione 5. : Convegno "Destini del sacro. Discorso religioso e semiotica delle culture"(23/11/2007 - 25/11/2007 - Facoltà di Scienze della Comunicazione e dell’Economia - Teatro Valli - Teatro Ariosto ; Reggio Emilia, Italia).

Corpus SCC (Sémiotique - Culture - Communication)ll XXXV congresso dell' AISS (Associazione Italiana di Studi Semiotici) dal titolo “Destini del sacro. Discorso religioso e semiotica delle culture”, è organizzato in collaborazione con la Facoltà di Scienze della Comunicazione dell’Università di Reggio Emilia. I differenti studiosi, molti di fama internazionale, si sono riuniti intorno ad un tema, quello del “sacro”, che in semiotica non è riconducibile immediatamente ad un’area di indagine dai contorni netti o a specifiche tecniche di analisi. Definire questa area, confrontare le diverse prospettive teoriche e le indagini testuali, è stato uno degli obiettivi del convegno. Cosa permette di definire “sacro” un testo? Quali sono le valenze semantiche che il termine “sacro” assume nelle diverse culture? È possibile pensare la sacralità come effetto di senso

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10 years follow up study

Background: Medullary thyroid carcinoma (MTC) is a well-differentiated thyroid tumor that maintains the typical features of C cells. An advanced stage and the presence of lymph node metastases at diagnosis have been demonstrated to be the most important bad prognostic factors. Somatic RET mutations have been found in 40–50% of MTCs. Although a relationship between somatic mutations and bad prognosis has been described, data are controversial and have been performed in small series with short-term follow ups. The aim of this study was to verify the prognostic value of somatic RET mutations in a large series of MTCs with a long follow up. Methods: We studied 100 sporadic MTC patients with a 10.2 yr mean follow-up. RET gene exons 10–11 and 13–16 were analyzed. The correlation between the presence/absence of a somatic RET mutation, clinical/pathological features, and outcome of MTC patients was evaluated. Results: A somatic RET mutation was found in 43 of 100 (43%) sporadic MTCs. The most frequent mutation (34 of 43, 79%) was M918T. RET mutation occurrence was more frequent in larger tumors (P = 0.03), and in MTC with node and distant metastases (P < 0.0001 and P = 0.02, respectively), thus, a significant correlation was found with a more advanced stage at diagnosis (P = 0.004). A worse outcome was also significantly correlated with the presence of a somatic RET mutation (P = 0.002). Among all prognostic factors found to be correlated with a worse outcome, at multivariate analysis only the advanced stage at diagnosis and the presence of a RET mutation showed an independent correlation (P < 0.0001 and P = 0.01, respectively). Finally, the survival curves of MTC patients showed a significantly lower percentage of surviving patients in the group with RET mutations (P = 0.006). Conclusions: We demonstrated that the presence of a somatic RET mutation correlates with a worse outcome of MTC patients, not only for the highest probability to have persistence of the disease, but also for a lower survival rate in a long-term follow up. More interestingly, the presence of a somatic RET mutation correlates with the presence of lymph node metastases at diagnosis, which is a known bad prognostic factor for the definitive cure of MTC patients

thyroid carcinoma

CDKN1B encodes the cyclin-dependent kinase inhibitor p27Kip1 and is mutated in multiple endocrine neoplasia-like syndromes. CDKN1B also harbors single nucleotide polymorphisms; the T/G transversion at nucleotide 326 (the V109G variant) has been reported to be protective in breast, hereditary prostate, and pancreatic tumors. Association of CDNK1B mutations or polymorphisms with sporadic medullary thyroid carcinoma (MTC) has not been investigated yet. We screened germline DNA from 84 patients affected by sporadic MTC and 90 healthy age- and gender-matched controls for CDKN1B mutations or polymorphisms by PCR amplification and sequencing of the amplicons. We also tested all germline and 50 tumor tissue DNA for RET proto-oncogene mutations. Computed tomography, ultrasound scans, and serum calcitonin were carried out before surgery and during the follow-up and associated with CDKN1B polymorphism and disease remission. The T/G transversion at nucleotide 326 was the only DNA variation detected. The overall frequency of the T/G and G/G alleles in combination was 46.4%. This variant (V109G) was correlated with post-operative calcitonin levels in the normal range and biochemical remission. Conversely, the wild-type (T/T) allele was associated with post-operative calcitonin levels above normal and a higher risk to develop clinical recurrence and distant metastases. Somatic RET mutations were significantly associated with a more aggressive behavior especially in wild-type allele-bearing patients. Collectively, in sporadic MTC, the CDKN1B V109G polymorphism correlates with a more favorable disease progression than the wild-type allele and might be considered a new promising prognostic marker

CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma

CONTEXT: CDKN1B encodes the cyclin-dependent kinase inhibitor p27Kip1 and is mutated in multiple endocrine neoplasia-like syndromes. CDKN1B also harbors single nucleotide polymorphisms; the T/G transversion at nucleotide 326 (the V109G variant) has been reported to be protective in breast, hereditary prostate, and pancreatic tumors. Association of CDNK1B mutations or polymorphisms with sporadic medullary thyroid carcinoma (MTC) has not been investigated yet. OBJECTIVE AND DESIGN: We screened germline DNA from 84 patients affected by sporadic MTC and 90 healthy age- and gender-matched controls for CDKN1B mutations or polymorphisms by PCR amplification and sequencing of the amplicons. We also tested all germline and 50 tumor tissue DNA for RET proto-oncogene mutations. Computed tomography, ultrasound scans, and serum calcitonin were carried out before surgery and during the follow-up and associated with CDKN1B polymorphism and disease remission. RESULTS: The T/G transversion at nucleotide 326 was the only DNA variation detected. The overall frequency of the T/G and G/G alleles in combination was 46.4%. This variant (V109G) was correlated with post-operative calcitonin levels in the normal range and biochemical remission. Conversely, the wild-type (T/T) allele was associated with post-operative calcitonin levels above normal and a higher risk to develop clinical recurrence and distant metastases. Somatic RET mutations were significantly associated with a more aggressive behavior especially in wild-type allele-bearing patients. CONCLUSIONS: Collectively, in sporadic MTC, the CDKN1B V109G polymorphism correlates with a more favorable disease progression than the wild-type allele and might be considered a new promising prognostic marker

The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 Years experience at one single center

BACKGROUND: Medullary thyroid carcinoma (MTC) is a calcitonin (CT)-producing C-cell tumor. In hereditary cases, a germline RET mutation is found in 98% of families. Because MTC is cured only if intrathyroidal, prophylactic thyroidectomy is recommended in the gene carrier (GC). AIMS: The aim was to determine whether thyroidectomy performed when stimulated CT becomes detectable is as safe as prophylactic thyroidectomy and to identify the serum CT cutoff able to distinguish intrathyroidal from extrathyroidal MTC. PATIENTS: Eighty-four GC were prospectively enrolled; 53 of the 84 underwent total thyroidectomy, one refused surgery, and 30 with normal basal and stimulated CT were under surveillance. The follow-up ranged from 2 to 18 yr. RESULTS: GC operated on for elevated stimulated CT included 27 GC with a positive peak CT at the screening and four cases who became positive after 4 yr. All of them had intrathyroidal MTC and no node metastases; all were cured after a mean follow-up of 7.5 yr. Among those operated on for detectable basal CT, intrathyroidal tumors were found when CT was below 60 pg/ml, whereas either node metastases or larger tumors were observed when CT was above 60 pg/ml. No correlation among serum CT, age, and type of RET mutation was observed. Thirty GC were still biochemically negative at the annual control. CONCLUSIONS: The time of thyroidectomy in GC with negative CT could be personalized and safely planned when stimulated CT becomes positive, independent of the type of RET mutation and patient's age. In this series, a basal CT below 60 pg/ml was always associated to an intrathyroidal localization of MTC